Gemcitabine suppresses malignant ascites of human pancreatic cancer: correlation with VEGF expression in ascites

  • Authors:
    • Kenichi Kuwahara
    • Tamito Sasaki
    • Kensou Kobayashi
    • Bunjirou Noma
    • Masahiro Serikawa
    • Tomohiro Iiboshi
    • Hideki Miyata
    • Yukio Kuwada
    • Masateru Murakami
    • Souichirou Yamasaki
    • Kenji Kariya
    • Kenji Morinaka
    • Kazuaki Chayama
  • View Affiliations

  • Published online on: January 1, 2004     https://doi.org/10.3892/or.11.1.73
  • Pages: 73-80
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

It has been reported that vascular endothelial growth factor (VEGF) is a potent angiogenic factor that also has the ability to increase vascular permeability. VEGF plays an important role in the development of malignant ascites in various cancers. Gemcitabine has been prescribed for patients with inoperable human pancreatic ductal carcinoma as a first-line chemotherapy. However, the response rates of patients with malignant ascites who were undergoing systemic chemotherapy were extremely limited. In the present study, we investigated the role of VEGF and the effects of gemcitabine on malignant ascites of human pancreatic ductal carcinoma. As an in vitro assay, the human pancreatic cancer cell line (SUIT-2) was incubated in DMEM supplemented with serially diluted concentrations of gemcitabine for 24 h. The expression levels of VEGF in culture media were assayed using an enzyme-linked immunosorbent assay (ELISA). As an in vivo assay, a cell suspension (1x107 cells in 100 µl PBS) was injected into the intraperitoneal region. The mice were randomly divided into two groups (control and treated with gemcitabine). The mice were sacrificed four weeks after inoculation, the ascites volume was measured, and the extent of peritoneal dissemination was examined. The expression levels of VEGF and CD31 in peritoneal nodules were examined by immunohistochemistry. In addition, secreted VEGF protein levels were quantified using ELISA. The results show that VEGF levels in the culture medium decreased in response to gemcitabine in a dose-dependent manner. The ascites formation and peritoneal dissemination within mice were suppressed by the treatment with gemcitabine. Immunohistochemical analysis suggested that expression of VEGF and CD31 in peritoneal nodules was suppressed by gemcitabine treatment, and the VEGF protein level in ascites was significantly decreased by gemcitabine (p<0.05). These results suggest that gemcitabine controls malignant ascites and peritoneal dissemination, either directly or indirectly, via VEGF. Moreover, intraperitoneal administration of gemcitabine may be a useful therapeutic approach for patients with malignant ascites in pancreatic carcinoma.

Related Articles

Journal Cover

January 2004
Volume 11 Issue 1

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Kuwahara K, Sasaki T, Kobayashi K, Noma B, Serikawa M, Iiboshi T, Miyata H, Kuwada Y, Murakami M, Yamasaki S, Yamasaki S, et al: Gemcitabine suppresses malignant ascites of human pancreatic cancer: correlation with VEGF expression in ascites. Oncol Rep 11: 73-80, 2004
APA
Kuwahara, K., Sasaki, T., Kobayashi, K., Noma, B., Serikawa, M., Iiboshi, T. ... Chayama, K. (2004). Gemcitabine suppresses malignant ascites of human pancreatic cancer: correlation with VEGF expression in ascites. Oncology Reports, 11, 73-80. https://doi.org/10.3892/or.11.1.73
MLA
Kuwahara, K., Sasaki, T., Kobayashi, K., Noma, B., Serikawa, M., Iiboshi, T., Miyata, H., Kuwada, Y., Murakami, M., Yamasaki, S., Kariya, K., Morinaka, K., Chayama, K."Gemcitabine suppresses malignant ascites of human pancreatic cancer: correlation with VEGF expression in ascites". Oncology Reports 11.1 (2004): 73-80.
Chicago
Kuwahara, K., Sasaki, T., Kobayashi, K., Noma, B., Serikawa, M., Iiboshi, T., Miyata, H., Kuwada, Y., Murakami, M., Yamasaki, S., Kariya, K., Morinaka, K., Chayama, K."Gemcitabine suppresses malignant ascites of human pancreatic cancer: correlation with VEGF expression in ascites". Oncology Reports 11, no. 1 (2004): 73-80. https://doi.org/10.3892/or.11.1.73